title: Helical tomotherapy: an innovative radiotherapy technique for the treatment of locally advanced oropharynx and inoperable oral cavity carcinoma.
abstract: BACKGROUND
  To report our initial clinical experience of helical tomotherapy (HT) in the treatment of locally advanced oropharynx and inoperable oral cavity cancer.
  
  
  METHODS
  Between February 2008 and January 2011, 24 consecutive patients, 15 with oropharyngeal cancer and 9 with oral cavity cancer were treated with exclusive radiotherapy or concomitant chemoradiotherapy. Simultaneous integrated boost (SIB) in 30 fractions scheme was prescribed to all patients, using Helical Tomotherapy. Doses administered to primary tumor, oropharynx/oral cavity and positive lymph-nodes and negative lymph-nodes were 66-67.5 Gy, 60-63 Gy and 54 Gy, respectively.
  
  
  RESULTS
  Complete response rate for the oropharynx and the oral cavity group was 86.7% and 77.8%, respectively. The 1 and 2-year Overall Survival (OS) and Disease Free Survival (DFS) rate for the oropharynx group was 92.9%, 85.1%, 92.9% and 77.4% respectively. For the oral cavity group, 1 and 2-year OS and DFS rates were 55.6%, 55.6%, 75% and 75%, respectively. No patient developed grade ≥3 mucositis, dysphagia or dermatitis. The maximum late-toxicity grade observed was 2, for all the variables examined.
  
  
  CONCLUSIONS
  HT appears to achieve encouraging clinical outcomes in terms of response, survival and toxicity rates.
authors.affiliation: Department of Radiation Oncology, San Camillo-Forlanini Hospital, Rome, Italy. vdonato@scamilloforlanini.rm.it.
authors.forename: Vittorio
authors.initials: V
authors.lastname: Donato
authors.forename: Michele
authors.initials: M
authors.lastname: Cianciulli
authors.forename: Sofia
authors.initials: S
authors.lastname: Fouraki
authors.forename: Leonardo
authors.initials: L
authors.lastname: Vigna
authors.forename: Alberto
authors.initials: A
authors.lastname: Rocco
authors.forename: Nicola
authors.initials: N
authors.lastname: Raffetto
authors.forename: Gianluca
authors.initials: G
authors.lastname: Bellocchi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D059248:Chemoradiotherapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D009959:Oropharyngeal Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D011878:Radiotherapy / Q000379:methods*; D011880:Radiotherapy Planning, Computer-Assisted; D036542:Tomography, Spiral Computed / Q000379:methods*
references.citation: Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1535-9
references.pmid: 15925457
references.citation: Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):917-23
references.pmid: 16751074
references.citation: Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):617-24
references.pmid: 14751535
references.citation: Radiother Oncol. 2010 Oct;97(1):86-91
references.pmid: 20826031
references.citation: Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e215-22
references.pmid: 21531515
references.citation: Radiother Oncol. 2001 Dec;61(3):275-80
references.pmid: 11730997
references.citation: Semin Radiat Oncol. 1999 Jan;9(1):108-17
references.pmid: 10196402
references.citation: J Clin Oncol. 2004 Jan 1;22(1):69-76
references.pmid: 14657228
references.citation: Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73
references.pmid: 15925451
references.citation: BMC Cancer. 2011 Jan 27;11:37
references.pmid: 21269518
references.citation: Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):715-21
references.pmid: 19879069
references.citation: Oral Oncol. 2010 Oct;46(10):727-33
references.pmid: 20850370
references.citation: Med Phys. 1993 Nov-Dec;20(6):1709-19
references.pmid: 8309444
references.citation: Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):43-50
references.pmid: 15093897
references.citation: IARC Monogr Eval Carcinog Risks Hum. 2004;83:1-1438
references.pmid: 15285078
references.citation: Semin Radiat Oncol. 2004 Apr;14(2):103-9
references.pmid: 15095256
references.citation: J Clin Oncol. 2006 May 10;24(14):2137-50
references.pmid: 16682732
references.citation: Lancet Oncol. 2010 Aug;11(8):781-9
references.pmid: 20451455
references.citation: IARC Monogr Eval Carcinog Risks Hum. 1988;44:1-378
references.pmid: 3236394
references.citation: Oncologist. 2007 May;12(5):555-64
references.pmid: 17522243